|
1
|
Azzoli CG, Baker S Jr, Temin S, Pao W,
Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et
al American Society of Clinical Oncology: American Society of
Clinical Oncology Clinical Practice Guideline update on
chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol.
27:6251–6266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abba MC, Fabris VT, Hu Y, Kittrell FS, Cai
WW, Donehower LA, Sahin A, Medina D and Aldaz CM: Identification of
novel amplification gene targets in mouse and human breast cancer
at a syntenic cluster mapping to mouse ch8A1 and human ch13q34.
Cancer Res. 67:4104–4112. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Melchor L, Saucedo-Cuevas LP, Muñoz-Repeto
I, Rodríguez-Pinilla SM, Honrado E, Campoverde A, Palacios J,
Nathanson KL, García MJ and Benítez J: Comprehensive
characterization of the DNA amplification at 13q34 in human breast
cancer reveals TFDP1 and CUL4A as likely candidate target genes.
Breast Cancer Res. 11:R862009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hung MS, Mao JH, Xu Z, Yang CT, Yu JS,
Harvard C, Lin YC, Bravo DT, Jablons DM and You L: Cul4A is an
oncogene in malignant pleural mesothelioma. J Cell Mol Med.
15:350–358. 2011. View Article : Google Scholar
|
|
6
|
Yasui K, Arii S, Zhao C, Imoto I, Ueda M,
Nagai H, Emi M and Inazawa J: TFDP1, CUL4A, and CDC16 identified as
targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology. 35:1476–1484. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nag A, Bagchi S and Raychaudhuri P: Cul4A
physically associates with MDM2 and participates in the proteolysis
of p53. Cancer Res. 64:8152–8155. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang J and Chen J: VprBP targets Merlin
to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation. Oncogene.
27:4056–4064. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang X, Gu X, Liu Y, Ding F, Gu X, Huan
Y, Ren L and Wang Y: Molecular cloning and expression analysis of
evolutionarily conserved stathmin from Gekko japonicus spinal cord.
Indian J Biochem Biophys. 46:289–293. 2009.PubMed/NCBI
|
|
10
|
Nishitani H, Shiomi Y, Iida H, Michishita
M, Takami T and Tsurimoto T: CDK inhibitor p21 is degraded by a
PCNA coupled Cul4 DDB1Cdt2 pathway during S phase and after UV
irradiation. J Biol Chem. 43:29045–29052. 2008. View Article : Google Scholar
|
|
11
|
Li T, Hung MS, Wang Y, Mao JH, Tan JL,
Jahan K, Roos H, Xu Z, Jablons DM and You L: Transgenic mice for
cre-inducible overexpression of the Cul4A gene. Genesis.
49:134–141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miranda-Carboni GA, Krum SA, Yee K, Nava
M, Deng QE, Pervin S, Collado-Hidalgo A, Galic Z, Zack JA, Nakayama
K, et al: A functional link between Wnt signaling and
SKP2-independent p27 turnover in mammary tumors. Genes Dev.
22:3121–3134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang YL, Hung MS, Wang Y, Ni J, Mao JH,
Hsieh D, Au A, Kumar A, Quigley D, Fang LT, et al: Lung
tumourigenesis in a conditional Cul4A transgenic mouse model. J
Pathol. 233:113–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim JE, Kim SJ, Lee BH, Park RW, Kim KS
and Kim IS: Identification of motifs for cell adhesion within the
repeated domains of transforming growth factor-beta-induced gene,
betaig-h3. J Biol Chem. 275:30907–30915. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Y, El-Gabry M and Hei TK: Loss of
Betaig-h3 protein is frequent in primary lung carcinoma and related
to tumorigenic phenotype in lung cancer cells. Mol Carcinog.
45:84–92. 2006. View
Article : Google Scholar
|
|
16
|
Zhao YL, Piao CQ and Hei TK:
Downregulation of Betaig-h3 gene is causally linked to tumorigenic
phenotype in asbestos treated immortalized human bronchial
epithelial cells. Oncogene. 21:7471–7477. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Irigoyen M, Pajares MJ, Agorreta J,
Ponz-Sarvisé M, Salvo E, Lozano MD, Pío R, Gil-Bazo I and Rouzaut
A: TGFBI expression is associated with a better response to
chemotherapy in NSCLC. Mol Cancer. 9:1302010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang L, Rong R, Sheikh MS and Huang Y:
Cullin-4A DNA damage-binding protein 1 E3 ligase complex targets
tumor suppressor RASSF1A for degradation during mitosis. J Biol
Chem. 286:6971–6978. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bondar T, Kalinina A, Khair L, Kopanja D,
Nag A, Bagchi S and Raychaudhuri P: Cul4A and DDB1 associate with
Skp2 to target p27Kip1 for proteolysis involving the COP9
signalosome. Mol Cell Biol. 26:2531–2539. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
El-Mahdy MA, Zhu Q, Wang QE, Wani G,
Praetorius-Ibba M and Wani AA: Cullin 4A-mediated proteolysis of
DDB2 protein at DNA damage sites regulates in vivo lesion
recognition by XPC. J Biol Chem. 281:13404–13411. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Ma G, Wang Q, Wen M, Xu Y, He X,
Zhang P, Wang Y, Yang T, Zhan P, et al: Involvement of CUL4A in
regulation of multidrug resistance to P-gp substrate drugs in
breast cancer cells. Molecules. 19:159–176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inal A, Kos FT, Algin E, Yildiz R,
Dikiltas M, Unek IT, Colak D, Elkiran ET, Helvaci K, Geredeli C, et
al: Gemcitabine alone versus combination of gemcitabine and
cisplatin for the treatment of patients with locally advanced
and/or metastatic pancreatic carcinoma: A retrospective analysis of
multicenter study. Neoplasma. 59:297–301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brodowicz T, Krzakowski M, Zwitter M,
Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits
K, Ulsperger E, et al Central European Cooperative Oncology Group
CECOG: Cisplatin and gemcitabine first-line chemotherapy followed
by maintenance gemcitabine or best supportive care in advanced
non-small cell lung cancer: A phase III trial. Lung Cancer.
52:155–163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ricci S, Antonuzzo A, Galli L, Tibaldi C,
Bertuccelli M, Lopes Pegna A, Petruzzelli S, Algeri R, Bonifazi V,
Fioretto ML, et al: Gemcitabine monotherapy in elderly patients
with advanced non-small cell lung cancer: A multicenter phase II
study. Lung Cancer. 27:75–80. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bumcrot D, Manoharan M, Koteliansky V and
Sah DW: RNAi therapeutics: A potential new class of pharmaceutical
drugs. Nat Chem Biol. 2:711–719. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Uchida H, Tanaka T, Sasaki K, Kato K,
Dehari H, Ito Y, Kobune M, Miyagishi M, Taira K, Tahara H, et al:
Adenovirus-mediated transfer of siRNA against survivin induced
apoptosis and attenuated tumor cell growth in vitro and in vivo.
Mol Ther. 10:162–171. 2004. View Article : Google Scholar : PubMed/NCBI
|
